# A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years

> **NCT04083196** · PHASE1 · COMPLETED · sponsor: **National Vaccine and Serum Institute, China** · enrollment: 90 (actual)

## Conditions studied

- HPV Infection
- HPV-Related Cervical Carcinoma

## Interventions

- **BIOLOGICAL:** 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04083196
- **Lead sponsor:** National Vaccine and Serum Institute, China
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-07
- **Primary completion:** 2021-10-13
- **Final completion:** 2021-10-13
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2021-11-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04083196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04083196, "A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04083196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*